Table 4 Disposition by patent ductus arteriosus therapy at the Children’s Hospitals Neonatal Consortium center.

From: Management of the patent ductus arteriosus among infants born at 23 to 32 weeks’ gestation between 2011 to 2022: a report from in the Children’s Hospitals Neonatal Consortium

 

No PDA therapy

Pharmacotherapy for PDA

Surgical ligation

Transcatheter PDA closure

Patients, n

12,636

3416

2954

1692

Disposition

Died, n (%)

1615 (12.8)

364 (10.7)

150 (5.1)

69 (4.1)

To home or foster care, n (%)

7998 (63.3)

2538 (74.3)

1452 (49.2)

778 (46)

Hospital stay >1 year, n (%)

95 (0.8)

9 (0.3)

10 (0.3)

17 (1)

Transfer to another hospital, n (%)

2928 (23.2)

505 (14.8)

1342 (45.4)

828 (48.9)

Length of NICU stay, days, median [IQR]

47 [12, 92]

101 [66,133]

80 [10,127]

42 [7,118]

Age at discharge to home or foster care, days, median [IQR]

96 [53,141]

103 [70,136]

97 [43,141]

97 [51,148.5]

PMA at discharge to home or foster care, weeks, median [IQR]

43 [39.6,48.3]

42.4 [39.6,46]

44.5 [41.3,49.6]

45.1 [42,50.4]

  1. Data presented as median (interquartile range, IQR) or number (percentage); columns are not mutually exclusive.
  2. PDA Patent ductus arteriosus, PMA Postmenstrual age.
Back to article page